Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Cancer Player Aadi Bioscience Downgraded: Analyst Highlights 'Worse Than Expected' Response Rates

Published 15/12/2023, 19:16
© Reuters.  Cancer Player Aadi Bioscience Downgraded: Analyst Highlights 'Worse Than Expected' Response Rates
AADI
-

Benzinga - by Vandana Singh, Benzinga Editor.

Friday, Aadi Bioscience Inc (NASDAQ: AADI) released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations.

H.C. Wainwright notes that nab-sirolimus achieved a 26% and 11% investigator-assessed objective response rate (ORR) in tumors-harboring TSC1 and TSC2 inactivating alterations, respectively; this is significantly lower than what was observed in the exploratory analysis of data from the AMPECT trial, wherein nine of 14 (64%) mTORi-naive TSC1/TSC2+ PEComa patients achieved a response.

Nevertheless, it's important to highlight the highly advanced condition of these patient groups, potentially affecting the response rate negatively. H.C. Wainwright currently lacks information regarding the specific tumor types in which the responses were observed.

The drug candidate also achieved an ORR of 44% (4/9) in PEComa patients harboring TSC1 or TSC2 inactivating alterations previously exposed to mTOR inhibitors.

After reviewing the preliminary interim data from TSC1 and TSC2-altered solid tumors, alongside the historical benchmarks for tumor-agnostic approvals, and considering the probability of FYARRO being designated for later-line patients upon potential approval in a tumor-agnostic manner, H.C. Wainwright has downgraded the stock from Buy to Neutral.

Price Action: AADI shares are down 56.70% at $2.3250 on the last check Friday.

Latest Ratings for AADI

DateFirmActionFromTo
Jan 2022JefferiesInitiates Coverage OnBuy
Nov 2021HC Wainwright & Co.MaintainsBuy
Oct 2021Cowen & Co.Initiates Coverage OnOutperform
View More Analyst Ratings for AADI

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.